Jiecan Zhou (J Zhou)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 14

Top Topics

Glycemic Control

Hodgkin Lymphoma

Top Venues

Cardiovascular diabetology

Expert review of clinical pharmacology

Clinical research in cardiology : official journal of the German Cardiac Society

Oxidative medicine and cellular longevity

This page only lists publications with an associated author ORCID identifier.

Publications

Bo Xu, Jiecan Zhou
Sodium-glucose cotransporter 2 inhibitors and renal cancer in the US FDA adverse event reporting system. European journal of clinical pharmacology (2024)
Jiecan Zhou, Bo Xu, Fazhong He, Yan Shu, Xiaoping Chen, Zhaoqian Liu, Bao Sun, Wei Zhang
Association of RASGRP1 polymorphism with vascular complications in Chinese diabetic patients with glycemic control and antihypertensive treatment. Cardiovascular diabetology 23 (1) (2024)
Bo Xu, B Kang, S Li, S Fan, Jiecan Zhou
Sodium-glucose cotransporter 2 inhibitors and cancer: a systematic review and meta-analysis. Journal of endocrinological investigation (2024)
Bo Xu, Bo Kang, Jiecan Zhou
Sodium glucose cotransporter 2 inhibitors with cardiac arrhythmias in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized placebo-controlled trials. Clinical research in cardiology : official journal of the German Cardiac Society 113 (6) (2024)
Jiecan Zhou, Bo Xu, Fazhong He, Yan Shu, Xiaoping Chen, Zhaoqian Liu, Bao Sun, Wei Zhang
Association of RASGRP1 polymorphism with vascular complications in Chinese diabetic patients with glycemic control and antihypertensive treatment. Cardiovascular diabetology 23 (1) (2024)
Bo Xu, Bo Kang, Fan Tang, Zunbo He, Jiecan Zhou
Association between sodium-glucose cotransporter 2 inhibitors and eye disorders: a systematic review and meta-analysis. Expert review of clinical pharmacology (2024)
Bo Xu, Jiecan Zhou
Oral complement factor D inhibitor danicopan for paroxysmal nocturnal hemoglobinuria. Expert review of clinical pharmacology (2024)
Jiecan Zhou, Bo Xu, Fazhong He, Yan Shu, Xiaoping Chen, Zhaoqian Liu, Bao Sun, Wei Zhang
Association of RASGRP1 polymorphism with vascular complications in Chinese diabetic patients with glycemic control and antihypertensive treatment. Cardiovascular diabetology 23 (1) (2024)
Jiecan Zhou, Bo Xu, Fazhong He, Yan Shu, Xiaoping Chen, Zhaoqian Liu, Bao Sun, Wei Zhang
Association of RASGRP1 polymorphism with vascular complications in Chinese diabetic patients with glycemic control and antihypertensive treatment. Cardiovascular diabetology 23 (1) (2024)
Bo Xu, Bo Kang, Jiecan Zhou
Sodium glucose cotransporter 2 inhibitors with cardiac arrhythmias in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized placebo-controlled trials. Clinical research in cardiology : official journal of the German Cardiac Society (2024)
Bo Xu, Shaoqian Li, Bo Kang, Shangzhi Fan, Canyu Chen, Weiyi Li, Jixiang Chen, Zunbo He, Fan Tang, Jiecan Zhou
Role of SLC5A2 polymorphisms and effects of genetic polymorphism on sodium glucose cotransporter 2 inhibitorsinhibitor response. Molecular biology reports (2023)
Bo Xu, Shaoqian Li, Bo Kang, Shangzhi Fan, Zunbo He, Jiecan Zhou
CD25-targeted antibody-drug conjugate camidanlumab tesirine for relapsed or refractory classical Hodgkin lymphoma. Investigational new drugs 40 (6) (2022)
Bo Xu, Shaoqian Li, Bo Kang, Jiecan Zhou
The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Cardiovascular diabetology 21 (1) (2022)
Wei Zhang, Jiecan Zhou, Yongchao Gao, Fazhong He, Heng Xu, Xiao-Ping Chen, Wei Zhang, Ling Chen
Fas-Associated Factor 1 Promotes Hepatic Insulin Resistance via JNK Signaling Pathway. Oxidative medicine and cellular longevity 2021 (2021)